The Journal of dermatological treatment最新文献

Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial. 依瓦马替尼在中度至重度特应性皮炎患者中的应用：一项3期临床试验的事后分析

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-01-29 DOI: 10.1080/09546634.2025.2596524

Chaoying Gu, Aijun Chen, Huibin Yin, Suwei Tang, Jinhua Xu

{"title":"Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial.","authors":"Chaoying Gu, Aijun Chen, Huibin Yin, Suwei Tang, Jinhua Xu","doi":"10.1080/09546634.2025.2596524","DOIUrl":"https://doi.org/10.1080/09546634.2025.2596524","url":null,"abstract":"Background: Ivarmacitinib (SHR0302) is a novel and highly selective Janus kinase 1 inhibitor for treating moderate to severe atopic dermatitis (AD).Objective: This study aimed to evaluate the impacts of patient characteristics on the efficacy and safety of Ivarmacitinib.Methods: This post-hoc analysis used data from a randomized, double-blind, placebo-controlled, multicenter phase 3 trial of Ivarmacitinib in patients with moderate to severe AD in which patients were randomized (1:1:1) to receive Ivarmacitinib 4 mg or 8 mg or placebo for 16 weeks. Subgroup analyses were conducted based on baseline characteristics.Results: At week 16, both Ivarmacitinib 4 or 8 mg showed better efficacy over placebo in achieving Eczema Area and Severity Index (EASI) 75, EASI 90, and Worst Itch Numeric Rating Scale (WI-NRS) score ≥4-point responses in most subgroups based on age, sex, body mass index, AD duration, Investigator's Global Assessment score, EASI score, WI-NRS score, body surface area involvement, history of comorbid allergies, or previous systemic therapies. The overall incidence of adverse events and most of the adverse events of special interest were similar between Ivarmacitinib and placebo across all subgroups.Conclusion: Ivarmacitinib demonstrated efficacy and good tolerability in treating moderate to severe AD with diverse patient characteristics.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2596524"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146088619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estimated cost savings and formulary coverage barriers in biosimilar adoption. 生物仿制药采用的估计成本节约和处方覆盖障碍。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-01-13 DOI: 10.1080/09546634.2025.2610921

Alina S Feng, I-Chun Lin, Christopher G Youn, Wilson Liao

引用次数: 0

Healthcare resource use of patients with mild-moderate psoriasis on systemic treatments: a UK single-center longitudinal retrospective cohort study. 轻中度牛皮癣患者系统治疗的医疗资源利用：一项英国单中心纵向回顾性队列研究

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-03-13 DOI: 10.1080/09546634.2026.2640305

Elizaveta Gribaleva, Erin Barker, Neil Hansell, Tejus Dasandi, Qin Neville, Angela Clifford, John Gregory, Laura Bojke, Joe W E Moss, Catherine H Smith, Jonathan Barker, Andrew E Pink

{"title":"Healthcare resource use of patients with mild-moderate psoriasis on systemic treatments: a UK single-center longitudinal retrospective cohort study.","authors":"Elizaveta Gribaleva, Erin Barker, Neil Hansell, Tejus Dasandi, Qin Neville, Angela Clifford, John Gregory, Laura Bojke, Joe W E Moss, Catherine H Smith, Jonathan Barker, Andrew E Pink","doi":"10.1080/09546634.2026.2640305","DOIUrl":"https://doi.org/10.1080/09546634.2026.2640305","url":null,"abstract":"Background: Healthcare resource utilization (HCRU) costs in those on conventional systemics for mild-moderate psoriasis are poorly described.Objectives: This study aimed to describe HRCU, disease severity and health-related quality of life in patients with mild-moderate psoriasis requiring systemic therapy.Methods: UK single-center retrospective longitudinal cohort study including adults with mild-moderate psoriasis (PASI < 10, no historical PASI ≥ 10, no prior biologics) on conventional systemic therapy with 3-year data capture from first PASI recording (2014-2019, pre-COVID). Patients discontinued due to reaching PASI ≥ 10, starting biologics or being lost to follow-up.Results: The median annual HCRU cost was £1923 (mean £3361), largely driven by visit costs. A total of 50.8% patients achieved a PASI ≤ 2 and 30.6% achieved PASI ≤ 2 and DLQI ≤ 5 during follow-up. The difference between the maximum and minimum PASI for a patient and follow-up time were statistically significant predictors of total costs (p < 0.05).Conclusion: Despite high healthcare costs, nearly half of the patients did not achieve clear/nearly clear skin. These data, in the context of reducing costs for biosimilars, may provide a basis to challenge care pathways and access criteria for 'high-cost' treatments.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2640305"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative efficacy of matrix phenolization and nail bed reconstruction for pincer nail deformity: a retrospective study. 基质酚化与甲床重建治疗钳甲畸形的疗效比较：回顾性研究。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-04-06 DOI: 10.1080/09546634.2026.2646007

Xiang Ji, Xi Yang, Ping Zhu, Zhe-Xi Li, Zi-Chen Zhou, Xin-Fang Li, Aneesha Suddul Ramlochun, Da-Guang Wang

{"title":"Comparative efficacy of matrix phenolization and nail bed reconstruction for pincer nail deformity: a retrospective study.","authors":"Xiang Ji, Xi Yang, Ping Zhu, Zhe-Xi Li, Zi-Chen Zhou, Xin-Fang Li, Aneesha Suddul Ramlochun, Da-Guang Wang","doi":"10.1080/09546634.2026.2646007","DOIUrl":"https://doi.org/10.1080/09546634.2026.2646007","url":null,"abstract":"Objective: To compare the efficacy and safety of matrix phenolization and nail bed reconstruction for pincer nail deformity (PND).Methods: This study included 34 patients with 37 nails divided into matrix phenolization group (n = 21) and nail bed reconstruction group (n = 16). The width index, height index, curvature index of nail plate and visual analog scale (VAS) of pain were recorded preoperatively, 6 and 12 months postoperatively. Early postoperative pain, treatment effect, postoperative complications and patient satisfaction were also recorded.Results: The width index was higher, and the height index, curvature index, and VAS were lower at 6 and 12 months after both surgeries (p < 0.05). At 6 months after surgery, the height index and curvature index of nail bed reconstruction were lower than matrix phenolization (p < 0.05). There was no significant difference in the width index and VAS between two groups. At 12 months after surgery, there was no significant difference in the width index, height index, curvature index and VAS between two groups. Two cases had recurrence after matrix phenolization and two cases had nail fold pain after nail bed reconstruction. All patients were satisfied.Conclusion: Matrix phenolization and nail bed reconstruction both showed good efficacy and safety in the treatment of PND. Matrix phenolization has simple operation, mild pain and fast postoperative recovery, which is recommended in clinical practice.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2646007"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147625281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influence of disease control and perceived risk on atopic dermatitis treatment decisions. 疾病控制和感知风险对特应性皮炎治疗决策的影响。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-04-27 DOI: 10.1080/09546634.2026.2655503

Allison R Loiselle, Jessica K Johnson, Wendy Smith Begolka

{"title":"Influence of disease control and perceived risk on atopic dermatitis treatment decisions.","authors":"Allison R Loiselle, Jessica K Johnson, Wendy Smith Begolka","doi":"10.1080/09546634.2026.2655503","DOIUrl":"https://doi.org/10.1080/09546634.2026.2655503","url":null,"abstract":"Objective: Patients with atopic dermatitis (AD) face an increasingly complex treatment landscape with prescription options that vary in efficacy, safety, and mode of administration. The aim of this study was to evaluate how real-world factors such as risk tolerance, side effect (SE) concerns, and disease control influence treatment decisions.Methods: A cross-sectional electronic survey (January-April 2025) of U.S. adults with self-reported AD and caregivers was conducted to assess how they weigh treatment benefits and risks. Negative binomial regression examined predictors of the number of SEs prioritized over rapid symptom relief when AD is at its worst.Results: Included respondents (796 adults, 113 caregivers) most frequently reported unknown long-term SEs (618; 68.0%), liver or kidney problems (610; 67.1%), and allergic reactions (538; 59.2%) as SEs of concern. Over one quarter (26.1%) prioritized avoidance of ≥5 SEs over rapid symptom relief. Caregivers prioritized 40% more SEs over rapid relief than adult patients (adj IRR, 1.40; 95% CI, 1.22-1.61). Higher willingness to take health-related risks was associated with prioritizing fewer SEs (adj IRR, 0.95; 95% CI, 0.93-0.96), but AD control status was not significantly associated with SE prioritization.Conclusion: These findings demonstrate that safety concerns strongly influence treatment decision-making in AD, underscoring the need for transparent, personalized discussions to support shared decision-making.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2655503"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Distinct ocular safety profiles of dupilumab and upadacitinib in atopic dermatitis: a real-world study with ophthalmological and microbiological assessment. dupilumab和upadacitinib治疗特应性皮炎的不同眼部安全性：一项具有眼科和微生物学评估的真实世界研究。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-05-08 DOI: 10.1080/09546634.2026.2667680

Paulina Stepinska, Kamila Zawadzinska-Halat, Maciej Pastuszczak

{"title":"Distinct ocular safety profiles of dupilumab and upadacitinib in atopic dermatitis: a real-world study with ophthalmological and microbiological assessment.","authors":"Paulina Stepinska, Kamila Zawadzinska-Halat, Maciej Pastuszczak","doi":"10.1080/09546634.2026.2667680","DOIUrl":"https://doi.org/10.1080/09546634.2026.2667680","url":null,"abstract":"Background: Dupilumab is highly effective in atopic dermatitis (AD) but is associated with ocular surface disease, whereas Janus kinase (JAK) inhibitors may have a more favorable ocular safety profile.Objectives: To compare ocular outcomes and conjunctival microbiology in patients with moderate-to-severe AD treated with dupilumab versus upadacitinib.Methods: In this prospective real-world study, adult patients were treated with dupilumab or upadacitinib and evaluated at baseline and after 16 weeks. Ocular assessment included the Ocular Surface Disease Index (OSDI) and Schirmer test. Conjunctival swabs were collected for culture. Dermatological outcomes were assessed using EASI and DLQI.Results: Ninety-six patients were included (upadacitinib, n = 52; dupilumab, n = 44). Both treatments significantly improved EASI and DLQI. Conjunctivitis occurred in 39.0% of dupilumab-treated patients and in none of the upadacitinib-treated patients (p < .001). OSDI improved with upadacitinib (-8.3) but worsened with dupilumab (+2.1) (p < .001). Schirmer test results and bacterial colonization did not differ between groups.Conclusions: Dupilumab and upadacitinib showed comparable dermatological efficacy but distinct ocular safety profiles. Dupilumab was associated with more frequent conjunctivitis and worsening ocular symptoms.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2667680"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quality of life and patient-reported side effects of low-dose oral minoxidil in treating female pattern hair loss. 低剂量口服米诺地尔治疗女性型脱发的生活质量和患者报告的副作用。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-02-25 DOI: 10.1080/09546634.2026.2633066

Divija Sharma, Lillian Mo, Deep Patel, Austin Piontkowski, Candice Medina, Kelly Hawkins, Neda Shokrian, Benjamin Ungar

{"title":"Quality of life and patient-reported side effects of low-dose oral minoxidil in treating female pattern hair loss.","authors":"Divija Sharma, Lillian Mo, Deep Patel, Austin Piontkowski, Candice Medina, Kelly Hawkins, Neda Shokrian, Benjamin Ungar","doi":"10.1080/09546634.2026.2633066","DOIUrl":"10.1080/09546634.2026.2633066","url":null,"abstract":"Female pattern hair loss (FPHL) significantly affects women's well-being and quality of life (QoL), and low-dose oral minoxidil (LDOM) has increasingly gained attention as a convenient and effective treatment option. Although hypertrichosis is reported more often with LDOM than with topical formulations, patient perceptions and tolerance of this side effect remain poorly understood. We conducted a telephone survey at a single institution among women with FPHL currently taking or previously treated with LDOM for at least one month to evaluate treatment effectiveness, QoL, and side effect burden using the Women's Androgenetic Alopecia Quality of Life Questionnaire (WAA-QOL). Among 102 participants, the median duration of LDOM use was 12 months. Hair loss severity improved from a median score of 7 to 4 on a 10-point scale. Unwanted hair growth occurred in 71.6% of patients, most commonly on the face, arms, and legs; however, 93.2% did not consider it a reason to discontinue treatment, and most cases were mild or moderate. WAA-QOL scores improved significantly from baseline (67 to 39, p<0.001), with no predictors of unwanted hair growth identified. Overall, patients experienced clinical and QoL improvements, supporting a favorable patient-centered profile for LDOM.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2633066"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dermatologic indications for microwave-induced local hyperthermia. 微波局部热疗的皮肤指征。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-01-06 DOI: 10.1080/09546634.2025.2605619

Aditya K Gupta, Elizabeth A Cooper, Menno T W Gaastra, Michael H Gold

{"title":"Dermatologic indications for microwave-induced local hyperthermia.","authors":"Aditya K Gupta, Elizabeth A Cooper, Menno T W Gaastra, Michael H Gold","doi":"10.1080/09546634.2025.2605619","DOIUrl":"https://doi.org/10.1080/09546634.2025.2605619","url":null,"abstract":"Objectives: The potential utility of a novel microwave device for the treatment of a variety of superficial dermatologic indications is reviewed.Materials and methods: The Swift® microwave system applies low-dose microwave energy (8 GHz) noninvasively using a precision applicator to directly target lesional tissue, while modulating power setting and application time to maintain patient comfort during heat application. The device has been approved for general dermatology use, with some models labeled more-specifically for HPV-associated lesions and actinic keratosis. New case treatment data and published case reports were reviewed for viral skin infection, fungal nail infection, nodular cystic acne, neoplastic skin lesions, hidradenitis suppurativa (HS), and intractable plantar keratosis (IPK).Results: Case reports demonstrate preliminary efficacy of microwave hyperthermia in viral skin infection, fungal nail infection, nodular cystic acne, and neoplastic skin lesions, with few reported adverse events. Microwaves additionally provided good pain control for the reviewed cases of HS and IPK.Conclusions: The data support a possible role for the microwave device in the studied indications. Microwave treatment may be more tolerable for patients than cryotherapy or laser comparators. More systematic investigation of microwave hyperthermia is warranted to better define optimum dosing regimens and efficacy, as well as a wider safety profile.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2605619"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145914448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Persistence of interleukin-17 and interleukin-23 inhibitors in patients with plaque psoriasis: a real-world study in Taiwan. 白介素-17和白介素-23抑制剂在斑块型银屑病患者中的持久性：台湾的一项真实世界研究。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-01-12 DOI: 10.1080/09546634.2025.2604952

Yu-Huei Huang, Youran Xu, Shu-Chen Chang, Yu-Jr Lin, Chia-Ling Chang, Grace Hui-Min Wu, Yongjing Zhang, Bryan Wahking, Hong Qiu, Chee Jen Chang

{"title":"Persistence of interleukin-17 and interleukin-23 inhibitors in patients with plaque psoriasis: a real-world study in Taiwan.","authors":"Yu-Huei Huang, Youran Xu, Shu-Chen Chang, Yu-Jr Lin, Chia-Ling Chang, Grace Hui-Min Wu, Yongjing Zhang, Bryan Wahking, Hong Qiu, Chee Jen Chang","doi":"10.1080/09546634.2025.2604952","DOIUrl":"https://doi.org/10.1080/09546634.2025.2604952","url":null,"abstract":"Objectives: IL-17 inhibitors (IL-17i) and IL-23 inhibitors (IL-23i) are advanced treatments for moderate-to-severe plaque psoriasis. This study aimed to assess the persistence of IL-17i and IL-23i in patients with plaque psoriasis in Taiwan, where a unique healthcare reimbursement policy makes biologic persistence highly reflective of real-world effectiveness.Methods: We conducted a retrospective cohort study in bio-naïve patients with plaque psoriasis in Taiwan using the Chang Gung Research Database. Persistence was defined as the duration from initiation to discontinuatin of a biologic agent. Patients who were diagnosed with plaque psoriasis and initiated an IL-17i or an IL-23i between January 2015 and December 2022 were included. Persistence rates were estimated by Kaplan-Meier methods, using discontinuation as the event of interest.Results: A total of 544 and 334 patients were included in the IL-17i and IL-23i cohorts, respectively. Numerically higher persistence was observed for IL-23i compared with IL-17i (p < 0.001). The 48-week and 96-week persistence rates were 71.3% (67.5-75.4%) and 55.2% (50.7-60.1%) for IL-17i, and 82.2% (78.1-86.6%) and 75.1% (70.1-80.5%) for IL-23i.Conclusions: These findings may inform clinical decision-making by healthcare providers, patients, and policymakers. Further research integrating richer clinical information with extended follow-up will allow deeper investigation of biologic treatment patterns in real‑world settings.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2604952"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145954614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of redness in rosacea with potassium-titanyl-phosphate (KTP) 532 nm laser with and without topical 1% ivermectin cream: a randomized split-face trial. 磷酸钾-钛基（KTP） 532 nm激光治疗酒渣鼻红肿，加或不加局部1%伊维菌素乳膏：一项随机裂面试验。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-03-04 DOI: 10.1080/09546634.2026.2635882

Kristine Heidemeyer, Simone Cazzaniga, Alexandra Junge, Mathias Lehmann, S Morteza Seyed Jafari, Nikhil Yawalkar, Laurence Feldmeyer, Simon Bossart

{"title":"Treatment of redness in rosacea with potassium-titanyl-phosphate (KTP) 532 nm laser with and without topical 1% ivermectin cream: a randomized split-face trial.","authors":"Kristine Heidemeyer, Simone Cazzaniga, Alexandra Junge, Mathias Lehmann, S Morteza Seyed Jafari, Nikhil Yawalkar, Laurence Feldmeyer, Simon Bossart","doi":"10.1080/09546634.2026.2635882","DOIUrl":"10.1080/09546634.2026.2635882","url":null,"abstract":"Objective: Facial erythema and telangiectasia in rosacea are commonly treated with vascular lasers. Combination with ivermectin 1% cream, may enhance outcomes when combined with laser therapy. This study assesses whether topical ivermectin improves the efficacy of Potassium Titanyl Phosphate (KTP) 532 nm laser for facial erythema in rosacea.Methods: This is a randomized, evaluator-blinded, split-face study. 24 patients with rosacea received four KTP laser sessions; one facial side was additionally treated daily with ivermectin 1% cream. The primary outcome was the change in Normalized Erythema Index (NEI). Secondary measures included Skin Redness Index (SRI), Clinical Erythema Assessment, Physician Global Assessment, telangiectasia score, inflammatory lesion counts, patient satisfaction, and safety.Results: At week 16, the combination side showed a significantly greater NEI reduction than laser alone (ΔNEI%: 16.6 vs 5.3; p = 0.04). No significant differences were observed in SRI, and all other scores. However, papule reduction across visits was significantly greater with ivermectin (p = 0.02). Both treatments were well tolerated, with no serious adverse events.Conclusion: KTP laser effectively reduces erythema and inflammatory lesions; adjunctive ivermectin may further enhance papulopustular lesions. The combination is well tolerated, suggesting a potential adjunctive role for topical ivermectin in laser-based rosacea therapy.Clinical trial register: clinicalTrials.gov (NCT06033352).","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2635882"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147350191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0